Fig. 2aFrom: Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, IndiaThe distribution of direct-acting antivirals (DAAs) treatment recommended from 2017 to 2021 among CKD patientsBack to article page